On February 16, 2022, FDA published a compounding threat alert describing the potential risks associated with at-household use of compounded ketamine nasal spray and several adverse function stories. The February 2022 compounding possibility inform also supplied information about Spravato, which is topic to a Threat Evaluation and Mitigation System